U.S. Markets closed
  • S&P 500

    3,768.25
    -27.29 (-0.72%)
     
  • Dow 30

    30,814.26
    -177.24 (-0.57%)
     
  • Nasdaq

    12,998.50
    -114.10 (-0.87%)
     
  • Russell 2000

    2,123.20
    -32.15 (-1.49%)
     
  • Crude Oil

    51.94
    -0.42 (-0.80%)
     
  • Gold

    1,825.40
    -4.50 (-0.25%)
     
  • Silver

    24.81
    -0.06 (-0.23%)
     
  • EUR/USD

    1.2086
    +0.0001 (+0.0121%)
     
  • 10-Yr Bond

    1.0970
    -0.0320 (-2.83%)
     
  • Vix

    24.34
    +1.09 (+4.69%)
     
  • GBP/USD

    1.3587
    +0.0004 (+0.0272%)
     
  • USD/JPY

    103.6950
    -0.1050 (-0.1012%)
     
  • BTC-USD

    35,841.14
    +138.21 (+0.39%)
     
  • CMC Crypto 200

    698.51
    -36.63 (-4.98%)
     
  • FTSE 100

    6,735.71
    -66.25 (-0.97%)
     
  • Nikkei 225

    28,296.32
    -222.86 (-0.78%)
     

Bronstein, Gewirtz & Grossman, LLC Notifies Boston Scientific Corporation (BSX) Investors of Investigation

·2 min read

NEW YORK, NY / ACCESSWIRE / November 18, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Boston Scientific Corporation ("Boston Scientific" or the "Company") (NASDAQ:BSX). Investors who purchased Boston Scientific securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/bsx.

The investigation concerns whether Boston Scientific and certain of its officers and/or directors have violated federal securities laws.

On November 17, 2020, Boston Scientific announced a global recall of all unused inventory of the Company's LOTUS Edge Aortic Valve System, citing "complexities associated with the product delivery system." Boston Scientific further announced that "[g]iven the additional time and investment required to develop and reintroduce an enhanced delivery system, the company has chosen to retire the entire LOTUS product platform immediately." On this news, Boston Scientific's stock price fell $3.00 per share, or 7.89%, to close at $35.03 per share on November 17, 2020.

If you are aware of any facts relating to this investigation, or purchased Boston Scientific shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/bsx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/617323/Bronstein-Gewirtz-Grossman-LLC-Notifies-Boston-Scientific-Corporation-BSX-Investors-of-Investigation